Common Contracts
110 similar Underwriting Agreement contracts by Quotient LTD, Gevo, Inc., Neos Therapeutics, Inc., others
Underwriting AgreementUnderwriting Agreement • April 19th, 2021 • PHX Minerals Inc. • Crude petroleum & natural gas • New York
QUOTIENT LIMITED 17,647,059 Ordinary Shares (no par value per Share) UNDERWRITING AGREEMENT September 10, 2020Underwriting Agreement • September 14th, 2020 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
Each of the undersigned, Franz Walt, Chief Executive Officer of Quotient Limited, a company organized under the laws of Jersey (the “Company”), and Peter Buhler, Chief Financial Officer of the Company, on behalf of the Company, does hereby certify pursuant to Section 6(k) of that certain Underwriting Agreement dated [●], 2020 (the “Underwriting Agreement”) among the Company and the Underwriters named therein, that as of [●], 2020:
Underwriting AgreementUnderwriting Agreement • September 1st, 2020 • Panhandle Oil & Gas Inc • Crude petroleum & natural gas • New York
EX-1.1 2 d671797dex11.htm EX-1.1 Execution Version QUOTIENT LIMITED 9,230,770 Ordinary Shares (no par value per Share) UNDERWRITING AGREEMENT December 6, 2018 UNDERWRITING AGREEMENT December 6, 2018 Jefferies LLC Cowen and Company, LLC As...Underwriting Agreement • May 5th, 2020 • New York
QUOTIENT LIMITED 12,000,000 Ordinary Shares (no par value per Share) UNDERWRITING AGREEMENT November 6, 2019Underwriting Agreement • November 12th, 2019 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
Each of the undersigned, Franz Walt, Chief Executive Officer of Quotient Limited, a company organized under the laws of Jersey (the “Company”), and Christopher Lindop, Chief Financial Officer of the Company, on behalf of the Company, does hereby certify pursuant to Section 6(k) of that certain Underwriting Agreement dated [•], 2019 (the “Underwriting Agreement”) among the Company and the Underwriters named therein, that as of [•], 2019:
Concrete Pumping Holdings, Inc.Underwriting Agreement • May 15th, 2019 • Concrete Pumping Holdings, Inc. • Construction - special trade contractors • New York
Concrete Pumping Holdings, Inc.Underwriting Agreement • May 6th, 2019 • Concrete Pumping Holdings, Inc. • Construction - special trade contractors • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • January 24th, 2019 • Selecta Biosciences Inc • Pharmaceutical preparations • New York
QUOTIENT LIMITED 9,230,770 Ordinary Shares (no par value per Share) UNDERWRITING AGREEMENT December 6, 2018Underwriting Agreement • December 11th, 2018 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
NEOS THERAPEUTICS, INC. 17,391,304 Shares of Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT November 6, 2018Underwriting Agreement • November 6th, 2018 • Neos Therapeutics, Inc. • Pharmaceutical preparations • New York
RA MEDICAL SYSTEMS, INC. [●] Shares Common Stock ($0.0001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • September 17th, 2018 • Ra Medical Systems, Inc. • Surgical & medical instruments & apparatus • New York
7,777,778 Shares Verastem, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • May 18th, 2018 • Verastem, Inc. • Pharmaceutical preparations • New York
ABPRO CORPORATION [●] Shares Common Stock ($[●] par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • May 2nd, 2018 • Abpro Corp • Pharmaceutical preparations • New York
8,422,877 Shares Verastem, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • December 18th, 2017 • Verastem, Inc. • Pharmaceutical preparations • New York
NEOS THERAPEUTICS, INC. 4,800,000 Shares of Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT June 26, 2017Underwriting Agreement • June 29th, 2017 • Neos Therapeutics, Inc. • Pharmaceutical preparations • New York
QUOTIENT LIMITED 7,000,000 Ordinary Shares (no par value per Share) UNDERWRITING AGREEMENT April 5, 2017Underwriting Agreement • April 7th, 2017 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
ELEVATE CREDIT, INC. [ ] Shares Common Stock ($0.0004 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • March 27th, 2017 • Elevate Credit, Inc. • Finance services • New York
NEOS THERAPEUTICS, INC. 5,000,000 Shares Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • February 3rd, 2017 • Neos Therapeutics, Inc. • Pharmaceutical preparations • New York
OBALON THERAPEUTICS, INC. [ ● ] Shares Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • September 26th, 2016 • Obalon Therapeutics Inc • Surgical & medical instruments & apparatus • New York
QUOTIENT LIMITED 2,800,000 Ordinary Shares (no par value per Share) UNDERWRITING AGREEMENT July 29, 2016Underwriting Agreement • August 3rd, 2016 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
SELECTA BIOSCIENCES, INC. Shares Common Stock ($0.0001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • June 8th, 2016 • Selecta Biosciences Inc • Pharmaceutical preparations • New York
QUOTIENT LIMITED 4,444,445 Ordinary Shares (no par value per Share) UNDERWRITING AGREEMENT February 4, 2016Underwriting Agreement • February 9th, 2016 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
Each of the undersigned, Paul Cowan, Executive Chairman & Chief Executive Officer of Quotient Limited, a company organized under the laws of Jersey (the “Company”), and Stephen Unger, Chief Financial Officer of the Company, on behalf of the Company, does hereby certify pursuant to Section 6(k) of that certain Underwriting Agreement dated [ ] (the “Underwriting Agreement”) among the Company and the Underwriters named therein, that as of [ ]
ELEVATE CREDIT, INC. [ ] Shares Common Stock ($0.0004 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • January 11th, 2016 • Elevate Credit, Inc. • Finance services • New York
SANCILIO PHARMACEUTICALS COMPANY, INC. [●] Shares Common Stock ($[●] par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • December 30th, 2015 • Sancilio Pharmaceuticals Company, Inc. • Pharmaceutical preparations • New York
GEVO, INC. 2,050,000 Series A Units Consisting of One Share of Common Stock ($0.01 par value per share) and a Series D Warrant to Purchase One Share of Common Stock 8,000,000 Series B Units Consisting of a Pre-Funded Series E Warrant to Purchase One...Underwriting Agreement • December 9th, 2015 • Gevo, Inc. • Industrial organic chemicals • New York
NEOS THERAPEUTICS, INC. [ ] Shares Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • July 13th, 2015 • Neos Therapeutics, Inc. • Pharmaceutical preparations • New York
GEVO, INC. 4,300,000 Units Consisting of One Share of Common Stock ($0.01 par value per Share) and One-Tenth of a Series C Warrant to Purchase One Share of Common Stock UNDERWRITING AGREEMENT May 14, 2015Underwriting Agreement • May 15th, 2015 • Gevo, Inc. • Industrial organic chemicals • New York
KLOX TECHNOLOGIES INC. [●] Shares Common Shares (no par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • April 27th, 2015 • Klox Technologies, Inc. • Pharmaceutical preparations • New York
CONCERT PHARMACEUTICALS, INC. 3,300,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 19th, 2015 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Each of the undersigned, Roger Tung, President and Chief Executive Officer of Concert Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Nancy Stuart, Chief Operating Officer of the Company, on behalf of the Company, does hereby certify pursuant to Section 6(i) of that certain Underwriting Agreement dated March 19, 2015 (the “Underwriting Agreement”) between the Company and, on behalf of the several Underwriters named therein, Wells Fargo Securities, LLC and JMP Securities LLC that as of [ ]
GEVO, INC. 33,250,000 Units Consisting of One Share of Common Stock ($0.01 par value per Share), a Series A Warrant to Purchase One Share of Common Stock and a Series B Warrant to Purchase One Share of Common Stock UNDERWRITING AGREEMENT January 29, 2015Underwriting Agreement • January 30th, 2015 • Gevo, Inc. • Industrial organic chemicals • New York
7,250,000 Shares Verastem, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 23rd, 2015 • Verastem, Inc. • Pharmaceutical preparations • New York
Verastem, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representatives, an aggregate of 7,250,000 shares (the “Firm Shares”) of common stock, $0.0001 par value per share (the “Common Stock”), of the Company. In addition, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 1,087,500 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the “Shares.” The Shares are described in the Prospectus which is referred to below.
RADIUS HEALTH, INC. 4,000,000 Shares Common Stock ($0.0001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • January 23rd, 2015 • Radius Health, Inc. • Pharmaceutical preparations • New York
FORM OF UNDERWRITING AGREEMENT] Capitala Finance Corp. [ ] Shares Common Stock, $0.01 par value per share Underwriting Agreement Underwriting AgreementUnderwriting Agreement • November 17th, 2014 • Capitala Finance Corp. • New York
Accepted and agreed to as of the date first above written, on behalf of themselves and the other several Underwriters named in Schedule A
RADIUS HEALTH, INC. 2,750,000 Shares Common Stock ($0.0001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • October 2nd, 2014 • Radius Health, Inc. • Pharmaceutical preparations • New York
Radius Health, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom you are acting as representatives, an aggregate of 2,750,000 shares (the “Firm Shares”) of common stock, $0.0001 par value per share (the “Common Stock”), of the Company. In addition, solely for the purpose of covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 412,500 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional Shares are hereinafter collectively sometimes referred to as the “Shares.” The Shares are described in the Prospectus which is referred to below.
GEVO, INC. 30,000,000 Units Consisting of One Share of Common Stock ($0.01 par value per Share) and a Warrant to Purchase 0.5 of a Share of Common Stock UNDERWRITING AGREEMENT July 31, 2014Underwriting Agreement • August 1st, 2014 • Gevo, Inc. • Industrial organic chemicals • New York
